Company Overview of Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc., a biotechnology company, develops hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer. The company focuses on the regulation of the hematopoietic (blood-forming) system. It develops human stem cell and antibody therapies for oncology applications and blood-related disorders. The company develops CLT-008, an off-the-shelf cell-based medicine, which facilitates the engraftment in cord blood transplants and treats neutropenia; and a cancer stem cell antibody discovery program that is focused on therapies for acute myelogenous leukemia, multiple myeloma, and myelodysplastic syndrome. Cellerant Therapeutics, Inc. was formerly ...
1531 Industrial Road
San Carlos, CA 94070
Founded in 2003
Key Executives for Cellerant Therapeutics, Inc.
Executive Director of Corporate Development
Director of Technology Transfer
Compensation as of Fiscal Year 2013.
Cellerant Therapeutics, Inc. Key Developments
Cellerant Therapeutics, Inc. Presents at World Stem Cell & Regenerative Medicine Congress, May-21-2013 through May-23-2013
May 18 13
Cellerant Therapeutics, Inc. Presents at World Stem Cell & Regenerative Medicine Congress, May-21-2013 through May-23-2013. Venue: Victoria Plaza, London, United Kingdom. Presentation Date & Speakers: May-21-2013, Ramkumar Mandalam, Chief Executive Officer, President and Director. May-22-2013, Ramkumar Mandalam, Chief Executive Officer, President and Director.
Cellerant Therapeutics, Inc. Appoints William Reed as Vice President, Clinical Development
Feb 13 13
Cellerant Therapeutics, Inc. announced the appointment of William Reed, M.D. as Vice President, Clinical Development. Dr. Reed joins Cellerant from Cerus Corporation, where he served as Director, Clinical Research and Medical Affairs and worked on the Phase 3 clinical development of a red blood cell system in sickle cell disease or thalassemia.
Cellerant Therapeutics, Inc. Receives SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia
Oct 8 12
Cellerant Therapeutics, Inc. announced that it has signed a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503. The SBIR Contract funds the development of CLT-009, a first-in-class, human allogeneic Megakaryocyte Progenitor Cell therapy for the treatment of thrombocytopenia in cancer patients and allows the company to conduct studies to enable an Investigational New Drug (IND) Application to be filed with the FDA in the next two years.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|